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M. C. Kapulu1, D. F. Da2, K. Miura3, Y Li1, A. M. Blagborough4, T. S. Churcher5, D. Nikolaeva1, 
A. R. Williams1, A. L. Goodman1, I. Sangare2, A. V. Turner1, M. G. Cottingham1, 
A. Nicosia6,7,8, U. Straschil4, T. Tsuboi9, S. C. Gilbert1, Carole A. Long3, R. E. Sinden1,4, 
S. J. Draper1, A. V. S. Hill1, A. Cohuet2 & S. Biswas1
Malaria transmission-blocking vaccines (TBVs) target the development of Plasmodium parasites 
within the mosquito, with the aim of preventing malaria transmission from one infected individual to 
another. Different vaccine platforms, mainly protein-in-adjuvant formulations delivering the leading 
candidate antigens, have been developed independently and have reported varied transmission-
blocking activities (TBA). Here, recombinant chimpanzee adenovirus 63, ChAd63, and modified 
vaccinia virus Ankara, MVA, expressing AgAPN1, Pfs230-C, Pfs25, and Pfs48/45 were generated. 
Antibody responses primed individually against all antigens by ChAd63 immunization in BALB/c 
mice were boosted by the administration of MVA expressing the same antigen. These antibodies 
exhibited a hierarchy of inhibitory activity against the NF54 laboratory strain of P. falciparum in 
Anopheles stephensi mosquitoes using the standard membrane feeding assay (SMFA), with anti-
Pfs230-C and anti-Pfs25 antibodies giving complete blockade. The observed rank order of inhibition 
was replicated against P. falciparum African field isolates in A. gambiae in direct membrane feeding 
assays (DMFA). TBA achieved was IgG concentration dependent. This study provides the first head-
to-head comparative analysis of leading antigens using two different parasite sources in two different 
vector species, and can be used to guide selection of TBVs for future clinical development using the 
viral-vectored delivery platform.
Malaria is still one of the world’s major infectious diseases and exerts a devastating burden on global 
public health. The development of an effective vaccine against Plasmodium falciparum remains an impor-
tant but elusive goal; to date, only low-level efficacies have been achieved by a handful of approaches 
in clinical studies1. The most advanced malaria vaccine candidate, currently in Phase III clinical trials, 
is based on the circumsporozoite protein (CSP), and aims to prevent infection of the vaccinated host2. 
Transmission-blocking vaccines (TBVs) target antigens expressed by the transmissible sexual-stages of 
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the parasite, as well as those expressed by the mosquito, and aim to reduce and/or block transmission to 
the vertebrate host3,4. Pre-clinical studies investigating TBVs have led to the development of a number of 
P. falciparum antigens as vaccine candidates of which Pfs230, Pfs25, and Pfs48/45 are well characterized. 
Different vaccine platforms utilizing these antigens have been used to raise antibodies with demonstrable 
transmission-blocking activity (TBA)5. However, to date only Pfs25 and its ortholog in P. vivax, Pvs25, 
have been tested in Phase Ia clinical trials6,7.
Pfs25 is expressed during macrogametogenesis within the mosquito midgut and persists throughout 
zygote, ookinete and early oocyst development. Pfs25 antigen-specific IgG demonstrate TBA and anti-
body titer correlates with ability to block parasite infectivity8–10. On the other hand, Pfs230 and Pfs48/45 
are expressed on the surface of gametocytes within the human host and have a role in gamete-gamete 
recognition within the vector blood meal11,12. Individuals living in malaria endemic areas can naturally 
develop antibodies against these two antigens13–16.
Recently it has been shown that mosquito midgut ligands that mediate parasite invasion can also be 
targeted as TBV candidate antigens. Expressed midgut proteins of Anopheles stephensi and A. gambiae 
such as carboxypeptidase B4,17,18 and a 135 amino acid fragment of the A. gambiae midgut glycopro-
tein, alanyl aminopeptidase N1 (AgAPN1) have been developed as potential TBV candidates. Antibodies 
raised against this fragment of AgAPN1 have demonstrated TBA in studies using both P. falciparum and 
P. berghei parasites in two different anopheline species, A. gambiae and A. stephensi19.
Despite the lack of any reported comparison of TBA, Pfs230, Pfs25 and Pfs48/45 are currently con-
sidered the leading TBV candidate antigens. Their ability to induce a transmission-blocking response has 
been examined in different laboratories, and the antigens have been expressed mainly as recombinant 
proteins produced in a variety of heterologous expression systems as well as delivered using vectored 
vaccine technologies20. The development of some TBVs, especially members of the six-cysteine family 
of proteins Pfs230 and Pfs48/45, has been significantly hampered by the difficulties associated with the 
expression of full-length, correctly folded native protein. The induction of transmission-blocking anti-
bodies targeting these antigens is critically dependent on conformationally correct immunogens21,22. In 
the case of Pfs230, the region spanning amino acids 443-1132, referred to as region C (Pfs230-C), has 
been shown to induce the most potent TBA23. For Pfs48/45, codon harmonization of the native sequence 
has led to the expression of full-length protein, that induces antibodies giving greater than 95% inhi-
bition of oocyst formation in both rodents and primates when formulated in the Montanide ISA-51 
adjuvant24. Pfs25 protein has been used alone or conjugated to highly immunogenic carriers such as 
outer-membrane protein complex (OMPC) of Neisseria meningitidis serogroup B25. Pfs25 has also been 
delivered in a heterologous prime-boost regime using human adenovirus serotype 5 (HuAd5) and mod-
ified vaccinia virus Ankara (MVA) viral-vectors eliciting antibodies that exhibit TBA26.
Traditionally, viral vectors have been used in prime-boost regimes primarily for the induction of 
antigen-specific T cells, but HuAd5 and ChAd63, in a prime-boost regime with MVA, have also been 
used to induce functional antibodies against blood-stage malaria antigens in both pre-clinical and Phase 
I/IIa clinical studies27–30. Although potent as an antigen delivery vector, HuAd5 has not been favored for 
translation into the clinic due to the presence of neutralizing antibodies from pre-existing infections in 
individuals living in malaria endemic areas31. To circumvent this, chimpanzee adenoviruses (which are 
reported to have lower pre-existing neutralizing antibodies) have been used31. This human-compatible 
delivery system provides a robust and versatile platform to enable the testing and screening of TBV 
candidate antigens expressed in situ, while avoiding potential differences in potency caused by variable 
purification of expressed proteins.
In this study we have used the ChAd63-MVA heterologous prime-boost regime to compare four 
TBV candidate antigens head-to-head to identify antigen(s) for future clinical development in this 
viral vectored vaccination platform. We investigated AgAPN1, Pfs25, Pfs48/45, and region C of Pfs230 
(Pfs230-C), and we assessed the ability of vaccine-induced IgG against these antigens to inhibit the devel-
opment of P. falciparum oocysts within the mosquito, in order to guide prioritization of these candidates 
for clinical development in this delivery platform. We report that vaccine-induced IgG against Pfs230-C 
and Pfs25 completely blocked transmission of P. falciparum both the laboratory clone NF54 and field 
isolates from Burkina Faso.
Results:
Generation and expression of TBV candidate antigens in ChAd63 and MVA viral vec-
tors. Recombinant ChAd63 and MVA vectors expressing Pfs25 were generated previously26. We 
designed and generated recombinant ChAd63 and MVA vaccines expressing three additional TBV can-
didate antigens: AgAPN1 based on the genome sequence of A. gambiae PEST strain; Pfs230-C and two 
versions of Pfs48/45 (Pfs48/45−NGln and Pfs48/45+NGln) based on the genomic sequence of the P. falci-
parum 3D7 clone (Table 1). For AgAPN1 and Pfs48/45 the signal peptide and glycosylphosphatidylin-
ositol (GPI) anchor were not included in the construct. The inserts were used to generate recombinant 
ChAd63 and MVA expressing the individual antigens (Supplementary Information).
To test the expression of the antigens, pENTR4-LPTOS shuttle plasmid DNA expressing each indi-
vidual antigen (under the control of the human cytomegalovirus (CMV) promoter32) was used to trans-
fect HEK293 cells. Immunoblots of supernatants and cell lysates showed expression of the antigens at 
the expected size (AgAPN1 at 112 kDa, Pfs230-C at 83.5 kDa, Pfs25 at 18.8 kDa and Pfs48/45−NGln at 
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46 kDa)26 (Fig.  1). For Pfs48/45+NGln the molecular weight of the expressed protein was higher than 
expected (~60 kDa) possibly due to glycosylation. In Supplementary Fig. 1D when the supernatant was 
treated with Peptide-N-Glycosidase (optimized for the efficient release of N-linked oligosaccharides) the 
protein was expressed at the predicted size (46 kDa). Recombinant proteins were detected in superna-
tant for AgAPN1, Pfs230-C, Pfs25 and Pfs48/45+NGln suggesting that the incorporation of the tPA signal 
peptide leads to secretion of the antigen which is thought to be optimal for antibody induction33. Higher 
molecular weight bands were observed for Pfs230-C and Pfs48/45+NGln which could be dimers or a result 
of protein aggregation.
Heterologous prime-boost immunization induces IgG responses against TBV candidate 
antigens. We have previously shown that anti-Pfs25 antibodies, induced after vaccination with the 
HuAd5-MVA heterologous prime-boost vaccine regime, are functional and block the transmission of P. 
falciparum in a standard membrane feeding assay (SMFA)26 A pilot study was performed to test whether 
the ChAd63-MVA heterologous prime-boost regime was also able to induce antibodies to AgAPN1, 
Pfs230-C, Pfs48/45−NGln, and Pfs48/45+NGln. Antigen-specific IgG was induced after the priming immu-
nization with ChAd63 expressing the individual antigens, which was boosted significantly following the 
administration of the corresponding recombinant MVA (data not shown). Immune responses observed 
in the pilot study justified further testing of the longevity of vaccine-induced antibody responses. It has 
been previously shown that responses to Pfs25 eight weeks post-prime are similar whether primed with 
HuAd5 or ChAd6326.
IgG responses in this study were assessed at days 14 and 55 post-prime and day 14 post-boost 
(Fig.  2). Using Wilcoxon matched-pairs signed rank test the corresponding recombinant MVA signifi-
cantly boosted the response to AgAPN1 (p = 0.008), Pfs230-C (p = 0.03) and Pfs48/45+NGln (p = 0.03). 
The increase in Pfs25 antibody response after the MVA boost was not statistically significant (p = 0.06). 
We have previously reported that MVA significantly boosts the antibody response to Pfs25 primed by 
HuAd526 and this is reproducible in other experiments when primed with ChAd63. In this particular 
experiment there was variability in the antibody response in the group of animals vaccinated against 
Pfs25 but we have repeated this experiment and seen less variability. The Pfs48/45−NGln (p = 0.09) anti-
body response was not significantly boosted by the MVA. When tested in the ELISA against recombinant 
protein produced using the wheat germ cell-free protein expression system, there was a consistent trend 
that the vaccine-induced IgG response against Pfs48/45+NGln compared to Pfs48/45−NGln (day 70) was 
higher. In order to assess the longevity of the antibody responses, the animals were monitored for ten and 
a half months post-boost. The responses were well maintained (no significant difference between day 70 
and day 350 by Friedman test with Dunn’s multiple comparison test), for all the antigens except Pfs25.
Vaccine-induced antibody responses recognize native parasite and mosquito proteins. To 
determine whether antibodies induced against Pfs230-C, Pfs25, Pfs48/45−NGln, and Pfs48/45+NGln recog-
nize the respective native parasite proteins, indirect immunofluorescence assays (IFA) were performed 
on parasite preparations (mature P. falciparum gametocytes or Pfs25DR3 P. berghei ookinetes) (Fig. 3). 
Surface staining of macrogametes with vaccine induced anti-Pfs230-C antibodies and ookinetes with 
anti-Pfs25 antibodies confirmed the ability of the antibodies to recognize native parasite protein. The 
anti-Pfs48/45+NGln antibodies stained the surface of exflagellating male gametes but no staining was 
observed with Pfs48/45−NGln antiserum (data not shown). Naïve and viral vector control serum (mice 
immunized with ChAd63-MVA expressing GFP) were used as negative controls and showed undetecta-
ble levels of staining (data not shown).
The anti-AgAPN1 serum recognized native antigen in an ELISA against midgut lysate from two 
strains of A. gambiae, Yaoundé and G3 (Fig. 4). Anti-AgAPN1 serum also recognized native AgAPN1 
Antigen Accession No.
Full αα 
length
αα in 
construct Features
AgAPN1(PEST) AGAP004809 1020 20–998
SP (1-19α α ); GPI 
anchor(997-1020α α ); 
No TMH; No N-glycan 
sites. No N-glycan sites is 
repeated.
Pfs230(3D7) PF3D7_0209000 3135 443–1132
SP (1-20α α ); GPI 
anchor(3119-3134α α ); No 
TMH; 13 N-glycan sites.
Pfs48/45(3D7) PF3D7_1346700 448 28–427
SP (1-27α α ); GPI 
anchor(428-448α α ); 1 
TMH; 7 N-glycan sites.
Table 1.  TBV candidate antigen sequences used for generation of ChAd63-MVA viral vectors. Strain 
shown in parenthesis after rather than under antigen abbreviation; α α : amino acid; SP: signal peptide; GPI: 
glycosylphosphatidylinositol; TMH: Transmembrane helix.
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by western blot using midgut lysate from both A. gambiae Yaoundé (reducing and non-reducing condi-
tions) and A. stephensi SDA500 (reducing condition) with similar banding patterns previously observed 
and described19 (Supplementary Fig. 1A). We also tested the anti-Pfs48/45−NGln and anti-Pfs48/45+NGln 
serum in a western blot using P. falciparum gametocyte lysate and they recognized a protein of 46 kDa 
(Supplementary Fig. 1B and C respectively).
Inhibition of P. falciparum NF54 development in A. stephensi by vaccine-induced 
IgG. Vaccine-induced antibodies against Pfs230-C, Pfs25, and Pfs48/45 have shown varying TBA 
against P. falciparum depending on the antigen delivery system used24,34. Antibodies against AgAPN1 
have been shown to inhibit the infectivity of both P. berghei and P. falciparum19,35. Here we performed a 
head-to-head comparison of the ability of antigen-specific IgG (induced against each antigen with a com-
mon vaccine platform) to reduce the intensity and prevalence of P. falciparum NF54 parasite infection 
in a laboratory-reared vector (A. stephensi) using SFMA. TBA of antibodies against Pfs230-C has been 
shown previously to be complement-dependent36,37, and thus all assays were performed in the presence 
of complement. To be able to distinguish antibody-specific inhibition from non-specific effects of mouse 
serum, total purified IgG was used.
IgG against Pfs230-C and Pfs25 showed complete inhibition of oocyst intensity and prevalence 
(p < 0.00001 for both) whereas anti-Pfs48/45+NGln IgG showed 99% inhibition of oocyst intensity and 
85% inhibition of oocyst prevalence (p < 0.00001 for both) (Fig.  5). The IgG were tested in another 
independent SMFA and anti-Pfs230-C, Pfs25 and Pfs48/45+NGln all gave > 89% of oocyst intensity 
Figure 1. Expression of TBV candidate antigens in adherent HEK293 cells. pENTR4-LPTOS 
shuttle plasmid DNA expressing (A) AgAPN1, (B) Pfs230-C, (C) Pfs25, (D) Pfs48/45− NGln, and (E) 
Pfs48/45+ NGln was used to transfect HEK293 cells and the supernatant and cell lysate were harvested. 5 μ g 
protein was loaded per lane and after staining the western blots were developed for 5 min. The figure shows 
western blots using day70 anti-serum (pooled from 5 mice) collected after ChAd63-MVA vaccination against 
the respective antigens. Untransfected supernatant and cell lysate were used as negative controls. Lanes: 
1- antigen-specific supernatant in reducing buffer; 2- antigen-specific supernatant in non-reducing buffer; 3- 
antigen-specific lysate in reducing buffer; 4- antigen-specific lysate in non-reducing buffer; 5- untransfected 
supernatant in non-reducing buffer; 6- untransfected supernatant in reducing buffer; 7- untransfected lysate 
in non-reducing buffer; 8- untransfected lysate in reducing buffer. A protein ladder is included in the figure 
for reference.
www.nature.com/scientificreports/
5Scientific RepoRts | 5:11193 | DOi: 10.1038/srep11193
Figure 2. Antigen-specific IgG responses in mice after immunization with ChAd63-MVA expressing 
TBV antigens. BALB/c mice (n = 5/group) were primed with 1 × 108 infectious units (IFU) of ChAd63 
(day 0) and boosted with 1 × 107 plaque forming units (PFU) of MVA (day 56) expressing the individual 
antigens AgAPN1, Pfs230-C, Pfs25, Pfs48/45−NGln, and Pfs48/45+NGln. The figure shows the total IgG 
response measured by standardized ELISA on days 14, 55, 70 and thereafter every 28 days up to day 350. 
IgG responses were log-transformed and expressed as antibody units (AU) represented as mean ± SEM. The 
AU are not directly comparable between antigens, except for Pfs48/45 where the same coating antigen and 
ELISA method was used. Wilcoxon matched-pairs signed rank test was used to assess differences between 
day 55 and day 70 responses, whilst Friedman test with Dunn’s multiple comparison test was used to 
determine significance between day 70 and day 350. p ≤ 0.05 was considered significant (see Results text).
Figure 3. Reactivity of vaccine-induced antibodies against Pfs230-C, Pfs25 and Pfs48/45+NGln to 
native parasite antigen. In vitro cultured Pfs25DR3 transgenic P. berghei ookinetes or P. falciparum NF54 
microgametes and macrogametes were stained with purified total IgG from pooled serum (n = 5) against 
Pfs25 (top panel) or antisera against Pfs230-C (middle panel) and Pfs48/45+NGln (bottom panel). Antibody 
binding was detected by Alexa Fluor® 488-conjugated goat anti-mouse IgG (green) and the DNA was 
stained with DAPI (blue). Scale bars, 2 μ m.
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(Supplementary Fig. 2). There was no statistically significant inhibition seen with anti-AgAPN1 (tested 
in two independent feeds) and anti-Pfs48/45−NGln IgG at the same IgG concentration.
Inhibition of African field isolates of P. falciparum in A. gambiae by vaccine-induced IgG. We 
also tested the IgG in a direct membrane feeding assay (DMFA) using P. falciparum parasites collected 
from gametocyte donors (children aged between 5 and 11 years) in Bobo-Dioulasso, Burkina Faso. This 
was tested using laboratory-adapted A. gambiae s.s, M molecular form, one of the predominant vectors 
for malaria transmission in this region. Although most TBV antigens have limited polymorphisms38, we 
wanted to assess whether the efficacy and the ranking of the antigens against P. falciparum NF54 would 
be replicated against field isolates in a second vector species.
Significant inhibition of oocyst intensity and prevalence consistent with the previous assay (Fig.  5) 
was seen with anti-Pfs230-C (complete inhibition, p < 0.00001 for both) and anti-Pfs25 (99%, and 81.8% 
respectively, p < 0.00001 for both) IgG (Fig.  6). Anti-Pfs48/45+NGln IgG only significantly inhibited the 
oocyst intensity (45.5%, p = 0.007) and not prevalence in this experiment (Fig. 6). There was no signif-
icant inhibition seen with anti-AgAPN1 and anti-Pfs48/45−NGln IgG. The percent inhibition seen with 
anti-Pfs48/45+NGln IgG was lower than anti-Pfs230-C and anti-Pfs25 IgG.
Anti-Pfs230-C and anti-Pfs25 IgG showed superior TBA (> 99% inhibition of oocyst intensity) than 
the other antigens (Fig. 6). We thus investigated the effect of reducing the concentration of anti-Pfs230-C 
and anti-Pfs25 IgG in the membrane feeding assay (Figs 7 and 8). When tested at 250 μ g/mL against a 
different gametocyte donor (BF002), both anti-Pfs230-C and anti-Pfs25 IgG still gave complete block-
ade. Significant inhibition of oocyst intensity and prevalence was also seen in this experiment with 
anti-Pfs230-C (p = 0.007 and p < 0.00001 respectively) and anti-Pfs25 (p < 0.00001 for both) IgG, with 
the same results observed at both 62.5 μ g/mL and 125 μ g/mL concentrations.
The anti-AgAPN1, anti-Pfs48/45−NGln and anti-Pfs48/45+NGln IgG were also tested in two further exper-
iments using gametocytes from two different donors (BF003 and BF004). In this study anti-AgAPN1 IgG 
still showed no significant effect on oocyst prevalence in any of the experiments. However, anti-AgAPN1 
IgG gave significant inhibition of oocyst intensity in one experiment (donor BF004, Control 2 in 
Supplementary Fig. 3) but this result was not replicated in any other feeds performed. The anti-Pfs48/45−
NGln (82% and 78%, p = 0.01 and p < 0.0001 respectively) and anti-Pfs48/45+NGln (100%, p < 0.0001 for 
both) IgG showed significant inhibition in one assay (Control 2, Supplementary Fig. 3), whilst only 
anti-Pfs48/45−NGln IgG showed significant inhibition of oocyst intensity (55%, p = 0.02) in the other 
(Control 1, Supplementary Fig. 3). Control 2 had a lower oocyst number (8.5 oocysts) which could be 
due to the difference in the gametocytes, either amount ingested or sex ratio. The difference in inhibition 
could also be due to polymorphism in Pfs48/45, which has been reported previously38,39 or the number 
of parasite clones (multiplicity of infection), which might be an additional source of Pfs48/45 polymor-
phism in a single feed.
In light of the above results, we also expressed two smaller fragments of AgAPN1 using recombinant 
viral vectors; one corresponding to the N terminal fragment (amino acids 61-195) reported by Dinglasan 
et al.19 (AgAPN1 Nterm) and the other consisting of amino acids 20-303 based on the domain struc-
ture of AgAPN1 (AgAPN1 DomI). Total IgG was purified from sera (d70) from mice vaccinated with 
ChAd63 and MVA expressing AgAPN1, AgAPN1 DomI and AgAPN1 Nterm and tested in a SMFA at 
750 μ g/mL and 375 μ g/mL (Supplementary Fig. 4). Anti-AgAPN1 and anti-AgAPN1 DomI IgG showed 
Figure 4. Reactivity of vaccine-induced antibodies to A. gambiae midgut lysate. BALB/c mice (n = 5) 
were vaccinated with ChAd63 expressing AgAPN1 (day 0) and boosted with the respective MVA (day 56). 
Antibody responses were measured on days 14, 55 and 70 by endpoint ELISA using midguts lysates obtained 
from A. gambiae Yaoundé and G3 strains. The data were log-transformed and are represented as mean ± 
SEM for the different time-points.
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no significant effect on oocyst intensity and oocyst prevalence. Anti-AgAPN1 Nterm IgG gave significant 
inhibition of oocyst intensity (48%, p = 0.02) at 375 μ g/mL but not 750 μ g/mL, suggesting marginal TBA.
Discussion:
Here we describe a head-to-head comparison of the leading transmission-blocking vaccine candidate 
antigens using a human-compatible vaccine platform (heterologous prime-boost viral vectored deliv-
ery). TBV candidate antigens have been previously assessed individually for their ability to block par-
asite infectivity to mosquitoes using a wealth of different delivery platforms. In this comparative study, 
anti-Pfs230-C and anti-Pfs25 antibodies induced after vaccination with this viral vectored regime showed 
superior transmission-blocking activity compared to Pfs48/45 and AgAPN1 (each antigen construct 
(with the exception of Pfs48/45−Ngln) was tested a total of 2–4 times by SMFA and 3 times by DMFA 
with very similar results). IgG raised against Pfs230-C and Pfs25 have consistently shown better (> 99%) 
TBA on both parasite infectivity and prevalence using both laboratory and field isolates of P. falciparum 
in A. stephensi and A. gambiae respectively. We have previously reported the use of this delivery system 
to induce functional antibodies to Pfs25 when expressed from a human adenovirus (HuAd5) and MVA26. 
This work provides additional evidence that the viral vectored delivery platform can induce functional 
antibodies against a range of candidate TBV antigens. This platform has been used successfully to induce 
functional antibodies against leading blood-stage malaria antigens in humans29,30,40, and used success-
fully to identify novel target antigens for further development41.
Figure 5. Effect of mouse IgG induced by ChAd63-MVA immunization on P. falciparum NF54 parasite 
infectivity in A. stephensi mosquitoes. Pooled day 70 serum (n = 5) was used to purify total IgG against 
each of the antigens. 655 μ g/mL of each of the total IgG was mixed with P. falciparum NF54 cultured 
gametocytes and fed to A. stephensi mosquitoes (n = 20) in SMFA. Midguts were dissected 7 days post-
feeding. Data points represent the number of oocysts in individual mosquitoes and the lines show the 
arithmetic mean (from one experiment). The table shows the number of mosquitoes dissected (N) per 
antigen, mean number of oocysts, percent inhibition of infection intensity and prevalence calculated 
relative to the IgG from mice immunized with vectors expressing GFP. GLMM with a zero-inflated negative 
binomial error structure was used to describe oocyst intensity whilst a binomial error structure was used to 
determine oocyst presence or absence. Uncertainty was generated using bootstrapping methodology. p ≤ 0.05 
was considered significant.
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The development of certain TBV candidate antigens has been hampered by the inability to express 
full-length correctly folded proteins, like the sexual-stage cysteine-rich protein Pfs48/45 which has 
conformation-dependent target epitopes42,43. The viral vector delivery platform enabled us to express 
these antigens and induce antigen-specific antibodies. The ChAd63 vaccine primed a detectable anti-
body response that increased over time and was boosted after the administration of MVA expressing 
the respective antigen. These data are in accordance with previous findings where an 8 week interval 
between prime and boost was shown to induce high-titer antibodies against blood-stage malaria antigens 
and Pfs2526,28.
The antibody response is sustained for all the antigens (except Pfs25) using this delivery system, 
without the need for additional booster vaccinations after the initial prime-boost regime in mice. A sus-
tained antibody response for at least one transmission season is likely to be essential to enable effective 
blockade in endemic areas. The decline in the antibody response to Pfs25 compared to the other antigens 
could be in part due to the inherent properties of the antigen. It has been reported previously that anti-
bodies against Pfs25 decline to 50–70% of the peak response in mice after six months of follow up25. To 
address this, Pfs25 protein has been conjugated to several carrier proteins in an attempt to make it more 
immunogenic. A sustained antibody response was achieved in rhesus monkeys only after chemically 
conjugating Pfs25 to the OMPC of N. meningitidis serogroup B and adsorption to aluminum hydroxy-
phosphate25. A recent study has demonstrated that the induction of CD4+ T cells following an adju-
vanted influenza vaccine predicted the persistence of the antibody response44, and several pre-clinical 
and clinical studies have shown that viral vectors induce strong T cell responses29,45. We did not assess 
the IgG subclass responses in this study but we have published previously that this viral vectored regime 
induces a mixed Th1/Th2 response26,45. The role of memory B cells which are important for a rapid recall 
Figure 6. Effect of mouse IgG induced by ChAd63-MVA immunization on infectivity of P. falciparum 
field isolate to A. gambiae mosquitoes. The purified IgG (from pooled serum (n = 5)) for each of the 
antigens and gametocyte positive donor (BF001) RBCs were used in a DMFA. The gametocytaemia of the 
donor was 30 gametocytes per 1000 leukocytes and the ratio of male:female gametocytes was 1.44. The 
plasma from the gametocyte positive donor blood was replaced with 500 μ g/mL IgG and immediately fed to 
A. gambiae mosquitoes. Midguts were dissected 7 days post-feeding. Data points represent the number of 
oocysts in individual mosquitoes and the lines show the arithmetic mean. The table shows the number of 
mosquitoes dissected (N) per antigen, mean number of oocysts, percent inhibition of infection intensity and 
prevalence calculated relative to the IgG from mice immunized with vectors expressing GFP. GLMM with a 
zero-inflated negative binomial error structure was used to describe oocyst intensity whilst a binomial error 
structure was used to determine oocyst presence or absence. Uncertainty was generated using bootstrapping 
methodology. p ≤ 0.05 was considered significant.
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response was also not assessed in this study, but viral vectored vaccination regimes have been shown to 
induce memory B cells in rhesus macaques27 and humans46. It will be important to further assess the 
role of CD4+ T cell help and memory B cells in the context of antibody responses to TBV candidate 
antigens, especially Pfs25 where antibody maintenance may be sub-optimal. In contrast to Pfs25, anti-
body responses to antigens such as Pfs230 and Pfs48/45 could potentially be boosted by natural infection 
and gametocyte exposure, but this requires experimental assessment. It has been shown in the P. berghei 
model that antibody responses induced by immunization with DNA encoding Pbs48/45 were boosted 
after a blood-stage challenge in mice47.
Our results suggest that there is a possible effect of N-glycosylation site substitution on conformation, 
immunogenicity and transmission-blocking activity of Pfs48/45. In previously published studies, expres-
sion of Pfs48/45 in vaccinia virus resulted in a glycosylated product that was considerably less immuno-
genic in mice resulting in a lowered ability to inhibit parasite infectivity to A. stephensi48,49. In contrast to 
the published data, the IgG against Pfs48/45−NGln (with N-glycosylation site substitutions) did not show 
any transmission blocking effect in the SMFA against P. falciparum NF54, but did recognize antigen in 
a Western blot. This could be due to the lower antibody response seen with this construct, or due to 
unintended alterations in functionally important, conformational B cell epitopes caused by amino acid 
substitutions. In only one of the DMFA did IgG against Pfs48/45−NGln show measurable TBA, but this 
was marginal and needs further investigation. Polymorphisms in Pfs48/45 have been reported in field 
Figure 7. TBA of anti-Pfs230-C at different concentrations in DMFA. Membrane feeds were performed 
as described in Fig. 6 using a range of anti-Pfs230-C (7) and anti-Pfs25 (8) IgG concentrations (shown 
in brackets on the x-axis). The gametocytaemia of the donor (BF002) was 10 gametocytes per 1000 
leukocytes and the ratio of male:female gametocytes was 0.59. The IgG was tested with non-heat-inactivated 
AB+ serum as a source of complement. Data points represent the number of oocysts in individual 
mosquitoes and the lines show the arithmetic mean. The table shows the number of mosquitoes dissected 
(N) per antigen, mean number of oocysts, percent inhibition of infection intensity and prevalence calculated 
relative to the IgG from mice immunized with vectors expressing GFP. GLMM with a zero-inflated negative 
binomial error structure was used to describe oocyst intensity whilst a binomial error structure was used to 
determine oocyst presence or absence. Uncertainty was generated using bootstrapping methodology. p ≤ 0.05 
was considered significant.
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isolates and this could explain the variability in TBA seen in the Burkina Faso studies38. The variability in 
TBA of antibodies against Pfs48/45 could also be dependent on the amount and sex ratio of gametocytes 
ingested. We conclude that further studies need to be done to understand the variability of TBA seen 
with IgG against Pfs48/45 and could include comparative assessment of the 10C region of Pfs48/4550. We 
are currently investigating further the impact of oocyst numbers in the control mosquitoes and antigen 
polymorphism on TBA in Burkina Faso. It is critical that such an approach be adopted for the screening 
of potential TBV candidate antigens as we have recently shown that vaccine efficacy needs to be tested 
against a range of parasite exposures to interpret laboratory results accurately51.
It was surprising that anti-AgAPN1 IgG induced by viral vectored prime-boost vaccination exhibited 
variable TBA. It has been shown previously that antibodies to an N-terminal fragment of AgAPN1 can 
block the development of both P. berghei and P. falciparum19,35. This difference in TBA could be due to 
the difference in construct design, although we have shown that the antibodies induced here recognize 
native antigen in both immunoblots and ELISA which provides evidence for recognition of the target 
antigen. It could also be due to presence or absence of O-linked glycosylation or due to the masking of 
transmission-blocking epitopes by other immunodominant epitopes52. This antigen remains an attractive 
candidate due to its effects on diverse Plasmodium species in different anopheline species but requires 
further investigation in this system.
Figure 8. TBA of anti-Pfs25 IgG at different concentrations in DMFA. Membrane feeds were performed 
as described in Fig. 6 using a range of anti-Pfs230-C (7) and anti-Pfs25 (8) IgG concentrations (shown 
in brackets on the x-axis). The gametocytaemia of the donor (BF002) was 10 gametocytes per 1000 
leukocytes and the ratio of male:female gametocytes was 0.59. The IgG was tested with non-heat-inactivated 
AB+ serum as a source of complement. Data points represent the number of oocysts in individual 
mosquitoes and the lines show the arithmetic mean. The table shows the number of mosquitoes dissected 
(N) per antigen, mean number of oocysts, percent inhibition of infection intensity and prevalence calculated 
relative to the IgG from mice immunized with vectors expressing GFP. GLMM with a zero-inflated negative 
binomial error structure was used to describe oocyst intensity whilst a binomial error structure was used to 
determine oocyst presence or absence. Uncertainty was generated using bootstrapping methodology. p ≤ 0.05 
was considered significant.
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It has been reported that antibodies against Pfs25 and Pfs28 have synergistic TBA when IgG against 
the two antigens are combined in an SMFA53 or when expressed as fusion protein in Saccharomyces 
cerevisiae54. Investigation of whether the same synergy could be achieved with anti-Pfs25 and Pfs230-C 
antibodies will be important, and also ways to combine the two antigens in a single delivery platform. 
It will also be important in the future to determine the IC50 (concentration of antigen-specific antibody 
required to inhibit 50 percent of oocyst development)55 of the antibodies against Pfs230-C and Pfs25 
against field isolates, in order to determine the concentration of IgG required for effective blockade in 
different transmission settings. The viral vector platform used in this study has a proven safety record in 
clinical trials targeting a range of pathogens30,56,57. The ability to induce antibody responses with func-
tional activity against TBV candidate antigens with inhibitory effects of up to 100% observed for two 
antigens is very encouraging for further development of these candidate vaccines for clinical trials.
Methods:
Design and generation of recombinant viral vectored vaccines. Antigen sequences for AgAPN1, 
(amino acids (aa) 20–998; AGAP004809, PEST strain), Pfs230 (PF3D7_0209000), Pfs48/45 (aa 28–427; 
PF3D7_1346700) and Pfs25 (aa 22–192; PF3D7_1031000) were obtained from NCBI protein database. 
For Pfs230, only region C (aa 443–1132, Pfs230-C) against which antibodies have been shown pre-
viously to inhibit parasite development was used58,59. All putative N-glycosylation sites were changed 
from Asn-Xaa-Ser/Thr to Gln-Xaa-Ser/Thr. For Pfs48/45 two different constructs were designed; one 
with all seven N-glycosylation sites43 substituted (Pfs48/45−NGln) and the other with the native amino 
acid sequence (Pfs48/45+NGln). In addition, two fragments of AgAPN1 were designed corresponding to 
amino acids 61–195 (AgAPN1 Nterm) and amino acids 20–303 (AgAPN1 DomI). The antigen sequences 
were codon optimized for expression in humans (GeneArt® Life Technologies, Germany) and the pre-
dicted native signal peptide for each antigen was replaced with the human tissue plasminogen activator 
(tPA) signal peptide28. The recombinant viral vaccines were generated as described in Supplementary 
Information.
Animal studies and vaccinations. Age-matched female BALB/c mice (Harlan, UK), housed in 
specific-pathogen free environments, were vaccinated via the intramuscular (i.m.) route using a heterol-
ogous prime-boost regime. To determine whether AgAPN1, Pfs230-C, Pfs48/45−NGln, and Pfs48/45+NGln 
were immunogenic when administered in this delivery system, which has been previously shown to 
elicit anti-Pfs25 specific antibodies26, a pilot study was undertaken. In all experiments, animals were 
vaccinated with a ChAd63 (day 0) priming dose of 1 × 108 IFU and boosted with MVA (day 56) at 
1 × 107 PFU expressing the individual test antigens. Control vaccinations were performed with ChAd63 
and MVA expressing green fluorescent protein (GFP). Vaccines were prepared in sterile endotoxin-free 
PBS (Invitrogen, UK). Vaccine-induced antibody responses were assessed on days 14, 55 and 70 and 
then every month for ten and a half months. All animal experiments and procedures were performed 
according to the UK Animals (Scientific Procedures) Act Project Licence (PPL 30/2414 and 30/2889) and 
approved by the Oxford University Local Ethical Review Committee.
Western Blot Analysis. To determine the expression of the recombinant antigens expressed by the 
constructs in mammalian cells, 1 × 107 cells/mL HEK293 cells were seeded onto 6 well plates and trans-
fected with pENTR™ (Invitrogen, UK) entry plasmid (containing the tetracycline operator in proximity 
to the TATA box, pENTR™4LPTOS)41) using Lipofectamine™ 2000 (Invitrogen, UK). Cells were incu-
bated overnight at 37 °C and 5% CO2. Supernatant and cell lysate were harvested in non-reducing, and 
reducing, SDS-PAGE loading buffers and boiled at 95 °C for 5 min before running on 8 or 12% poly-
acrylamide gels (Thermo Scientific, UK) (5 μ g/lane). Proteins were transferred onto 0.45 μ m nitrocel-
lulose membranes, which were then blocked in 3% BSA/PBS overnight, washed twice with PBS/0.05% 
Tween®20 (PBS/T) and incubated with sera (pooled d70 serum from all mice (n = 5) immunized with 
the respective antigens) diluted 1:100 in 3% BSA/PBS for 1 h. The blots were then washed and incubated 
for 1 h with donkey anti-mouse IgG AP-conjugated antibody (Jackson ImmunoResearch Laboratories, 
Inc.) diluted at 1:5000, in 3% BSA/PBS. After repeating the washing procedure, the protein bands were 
detected using BCIP/NBT alkaline phosphatase substrate (Sigma, UK) and after 5 min the images were 
scanned using Canon Canoscan LiDe200. Color plus Pre-stained Protein ladders (NEB, UK) were used 
to estimate the relative protein mobility.
ELISAs. To detect antigen-specific IgG antibodies induced by vaccination, ELISAs were performed as 
previously described10,60. The recombinant proteins for AgAPN1, Pfs230-C and Pfs48/45 were produced 
using the wheat-germ cell free system61 and the Pfs25 protein antigen was provided by Dr Yimin Wu 
(NIH, USA). A standard reference serum was created using pooled day 70 vaccinated mouse serum 
with high titers to the respective antigens. The standard reference was used on a standardized ELISA 
to determine the ELISA units, expressed as antibody units (AU), for each individual antigen. For Pfs25 
ELISAs, a previously reported standard serum was used10,25. A negative control (pooled serum from mice 
immunized with ChAd63 and MVA expressing GFP) was included and the OD values for the negative 
control were less than 0.15 for all the plates tested.
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Indirect Immunofluorescence Assay. P. falciparum gametocytes were cultured as described pre-
viously10 and pelleted. For gametocyte preparations, cultures were split and half were activated in ook-
inete media62, following which samples were fixed for 10 min in 4% PFA in PBS. The non-activated 
and activated preparations were then pipetted onto poly-Lysine coated multiwell slides, air dried and 
allowed to settle for 12 h, to allow the adherence of parasites and red blood cells (RBCs) to slides. Slides 
were then washed three times in Tris-buffered saline (TBS) and blocked using 10% goat serum (Sigma, 
UK) in 1% BSA/PBS for 1 h. The slides were incubated for 1 h with day 70 mouse antisera (Pfs230-C, 
Pfs48/45−NGln, and Pfs48/45+NGln) or purified total IgG (2.5 mg/ml for Pfs25) diluted 1:100 in 1%BSA/
PBS. After washing three times in TBS, goat anti-mouse IgG conjugated to Alexa Fluor 488 (Invitrogen, 
UK; 1:500 in 1% BSA/PBS) was added for 1 h, washed off in TBS and mounted with Vectashield/DAPI 
(Vector Labs, UK). The slides were visualized under x100 objective magnification using a fluorescence 
microscope (Leica DMI 3000 B, Leica Microsystems, UK). To assess antibody reactivity with native Pfs25 
on ookinetes, Pfs25DR3 transgenic P. berghei parasites described previously26 expressing Pfs25 were used. 
Phenylhydrazine (6 μ g/mL in PBS; Sigma, UK) treated female TO (Harlan, UK) mice were injected with 
1 × 107 Pfs25DR3 parasitized RBCs (pRBCs). Parasitized blood was harvested from the infected mouse 
and added 1:25 to ookinete media and left overnight at 19 °C. After 24 h, smears were fixed in 4% PFA 
in PBS after air-drying. Thereafter the procedure was carried out as outlined above.
IgG Purification. Total IgG was purified from day 70 pooled mouse sera (equal volume of serum from 
all mice in a group was pooled irrespective of individual antibody titer) from test and control (vectors 
expressing GFP) groups as described previously55 using Protein G columns (Pierce, USA). Briefly, Protein 
G columns were equilibrated with binding buffer (Immunopure IgG, Pierce, USA) after which a 1:1 
mixture of sera and binding buffer was allowed to flow through under gravity, washed and eluted with 
elution buffer (Immunopure IgG, Pierce, USA). The eluted fraction was collected in 1 M Tris-HCl (pH 
9.0, Teknova, USA) and transferred for buffer exchange to Amicon centrifugal filters (Millipore, USA) 
using PBS. The eluent was concentrated in PBS (Invitrogen, UK) and filtered using a 0.22 μ m Millipore 
Ultrafree sterile centrifugal unit. Total protein was quantified using a NanoDrop spectrophotometer at 
280 nm and adjusted to either 2.5 mg/mL, 3.5 mg/mL or 4 mg/mL.
Transmission-Blocking Assays. The ability of vaccine-induced antibodies to block the development 
of P. falciparum strain NF54 was assayed using gametocyte cultures as previously described10. In the case 
of cultured NF54 parasites, the percentage of mature Stage V gametocytes was adjusted to 0.15% ± 0.05% 
and the male-female ratio is stable (almost always 1 male : 2–3 female). These were mixed with purified 
IgG (diluted at 1/5.34 from adjusted total concentration of either 2.5 mg/mL, 3.5 mg/mL or 4 mg/mL 
giving a testing dilution of either 0.500 mg/mL, 0.655 mg/mL or 0.75 mg/mL respectively) and then fed 
to 4–6 day old starved female A. stephensi (SDA 500) via a parafilm® membrane. The purified IgG was 
diluted in non-heat-inactivated human AB+ sera. Purified IgG from a group of mice vaccinated with 
viral vectors expressing GFP was used as negative control. Infected mosquitoes were then maintained at 
26 °C and 80% relative humidity. After 7 days midguts from twenty mosquitoes were dissected, oocysts 
counted and the number of infected mosquitoes recorded. Percent reduction in infection intensity and 
prevalence were calculated relative to the control.
To determine the TBA against field isolates of P. falciparum, children aged between 5–11 years in 
Bobo-Dioulasso, Burkina Faso, were screened for the presence of asexual- and sexual-stage P. falciparum 
parasites by thick blood smears. Informed consent from parents or guardians was obtained for children 
positive for gametocytes (Protocol 003-2009/CE-CM, Centre Muraz institutional ethical committee). 
10 mL blood was drawn in heparinized tubes to obtain gametocytes. The plasma from the gametocyte 
positive donor blood was replaced by AB+ serum from a European donor, the purified IgG were added 
at 0.500 mg/mL in the final mixture and immediately fed to A. gambiae via a parafilm® membrane. 
Thereafter the procedure was carried out as outlined above. All SMFA and DMFA experiments were 
performed using non-heat-inactivated AB+ serum as a source of complement.
Statistical Analysis. For the ELISA data, Wilcoxon matched-pairs signed rank test was used to deter-
mine statistical significance between pre- and post-boost (day 55 and day 70) response and Mann-Whitney 
test between Pfs48/45−NGln and Pfs48/45+NGln (day 70 responses). To determine significance of the lon-
gevity of the vaccine-induced antibody response, a Friedman test with Dunn’s correction was used to 
assess differences between time-points for each individual test antigen. Ability of vaccine-induced anti-
bodies to inhibit oocyst intensity and prevalence of P. falciparum in transmission-blocking assays was 
assessed using generalized linear mixed models (GLMM) according to previously published methods51. 
A zero-inflated negative binomial error structure was used to describe oocyst intensity whilst a bino-
mial error structure was used to determine oocyst presence or absence. Models were compared using a 
likelihood ratio test and confidence intervals generated using bootstrapping methodology. Significance 
was taken as p < 0.05.
www.nature.com/scientificreports/
13Scientific RepoRts | 5:11193 | DOi: 10.1038/srep11193
References
1. Birkett, A. J., Moorthy, V. S., Loucq, C., Chitnis, C. E. & Kaslow, D. C. Malaria vaccine R&D in the Decade of Vaccines: 
breakthroughs, challenges and opportunities. Vaccine 31 Suppl 2, B233–243 (2013).
2. Agnandji, S. T. et al. A phase 3 trial of RTS,S/AS01 malaria vaccine in African infants. N Engl J Med 367, 2284–2295 (2012).
3. Carter, R. Transmission blocking malaria vaccines. Vaccine 19, 2309–2314 (2001).
4. Lavazec, C. & Bourgouin, C. Mosquito-based transmission blocking vaccines for interrupting Plasmodium development. 
Microbes and infection / Institut Pasteur 10, 845–849 (2008).
5. Carter, R., Mendis, K., Miller, L., Molineaux, L. & Saul, A. Malaria transmission-blocking vaccines--how can their development 
be supported? Nat Med 6, 241–244 (2000).
6. Malkin, E. M. et al. Phase 1 vaccine trial of Pvs25H: a transmission blocking vaccine for Plasmodium vivax malaria. Vaccine 23, 
3131–3138 (2005).
7. Wu, Y. et al. Phase 1 trial of malaria transmission blocking vaccine candidates Pfs25 and Pvs25 formulated with montanide ISA 
51. PLoS One 3, e2636 (2008).
8. Kaslow, D. et al. A vaccine candidate from the sexual stage of human malaria that contains EGF-like domains. Nature 333, 
74–76 (1988).
9. Barr, P. et al. Recombinant Pfs25 protein of Plasmodium falciparum elicits malaria transmission-blocking immunity in 
experimental animals. J Exp Med 174, 1203–1208 (1991).
10. Miura, K. et al. Transmission-blocking activity induced by malaria vaccine candidates Pfs25/Pvs25 is a direct and predictable 
function of antibody titer. Malar J 6, 107 (2007).
11. Eksi, S. et al. Malaria transmission-blocking antigen, Pfs230, mediates human red blood cell binding to exflagellating male 
parasites and oocyst production. Mol Microbiol 61, 991–998 (2006).
12. van Dijk, M. R. et al. A central role for P48/45 in malaria parasite male gamete fertility. Cell 104, 153–164 (2001).
13. Bousema, T. et al. The dynamics of naturally acquired immune responses to Plasmodium falciparum sexual stage antigens Pfs230 
& Pfs48/45 in a low endemic area in Tanzania. PLoS One 5, e14114 (2010).
14. Bousema, J. et al. A longitudinal study of immune responses to Plasmodium falciparum sexual stage antigens in Tanzanian 
adults. Parasite Immunol 29, 309–317 (2007).
15. Healer, J., McGuinness, D., Carter, R. & Riley, E. Transmission-blocking immunity to Plasmodium falciparum in malaria-
immune individuals is associated with antibodies to the gamete surface protein Pfs230. Parasitology 119 ( Pt 5), 425–433 (1999).
16. Roeffen, W. et al. Association between anti-Pfs48/45 reactivity and P. falciparum transmission-blocking activity in sera from 
Cameroon. Parasite Immunol 18, 103–109 (1996).
17. Lavazec, C. et al. Carboxypeptidases B of Anopheles gambiae as Targets for a Plasmodium falciparum Transmission-Blocking 
Vaccine. Infect. Immun. 75, 1635–1642 (2007).
18. Raz, A., Dinparast Djadid, N. & Zakeri, S. Molecular characterization of the carboxypeptidase B1 of Anopheles stephensi and its 
evaluation as a target for transmission-blocking vaccines. Infection and immunity 81, 2206–2216 (2013).
19. Dinglasan, R. R. et al. Disruption of Plasmodium falciparum development by antibodies against a conserved mosquito midgut 
antigen. Proc Natl Acad Sci U S A 104, 13461–13466 (2007).
20. Nikolaeva, D., Draper, S. J. & Biswas, S. Toward the development of effective transmission-blocking vaccines for malaria. Expert 
review of vaccines, 1–28, doi:10.1586/14760584.2015.993383 (2015).
21. van Dijk, M. R. et al. Three members of the 6-cys protein family of Plasmodium play a role in gamete fertility. PLoS Pathog 6, 
e1000853 (2010).
22. Williamson, K. C., Fujioka, H., Aikawa, M. & Kaslow, D. C. Stage-specific processing of Pfs230, a Plasmodium falciparum 
transmission-blocking vaccine candidate. Mol Biochem Parasitol 78, 161–169 (1996).
23. Williamson, K. C., Keister, D. B., Muratova, O. & Kaslow, D. C. Recombinant Pfs230, a Plasmodium falciparum gametocyte 
protein, induces antisera that reduce the infectivity of Plasmodium falciparum to mosquitoes. Mol Biochem Parasitol 75, 33–42 
(1995).
24. Chowdhury, D. R., Angov, E., Kariuki, T. & Kumar, N. A potent malaria transmission blocking vaccine based on codon 
harmonized full length Pfs48/45 expressed in Escherichia coli. PLoS One 4, e6352 (2009).
25. Wu, Y. et al. Sustained high-titer antibody responses induced by conjugating a malarial vaccine candidate to outer-membrane 
protein complex. Proc Natl Acad Sci USA 103, 18243–18248 (2006).
26. Goodman, A. L. et al. A viral vectored prime-boost immunization regime targeting the malaria Pfs25 antigen induces 
transmission-blocking activity. PLoS One 6, e29428 (2011).
27. Draper, S. J. et al. Enhancing blood-stage malaria subunit vaccine immunogenicity in rhesus macaques by combining adenovirus, 
poxvirus, and protein-in-adjuvant vaccines. J Immunol 185, 7583–7595 (2010).
28. Draper, S. J. et al. Effective induction of high-titer antibodies by viral vector vaccines. Nat Med 14, 819–821 (2008).
29. Sheehy, S. H. et al. Phase Ia clinical evaluation of the Plasmodium falciparum blood-stage antigen MSP1 in ChAd63 and MVA 
vaccine vectors. Mol Ther 19, 2269–2276 (2011).
30. Sheehy, S. H. et al. ChAd63-MVA-vectored blood-stage malaria vaccines targeting MSP1 and AMA1: assessment of efficacy 
against mosquito bite challenge in humans. Mol Ther 20, 2355–2368 (2012).
31. Dudareva, M. et al. Prevalence of serum neutralizing antibodies against chimpanzee adenovirus 63 and human adenovirus 5 in 
Kenyan children, in the context of vaccine vector efficacy. Vaccine 27, 3501–3504 (2009).
32. Sridhar, S. et al. Single-Dose Protection against Plasmodium berghei by a Simian Adenovirus Vector Using a Human 
Cytomegalovirus Promoter Containing Intron A. J. Virol. 82, 3822–3833 (2008).
33. Biswas, S. et al. Transgene Optimization, Immunogenicity and In Vitro Efficacy of Viral Vectored Vaccines Expressing Two 
Alleles of Plasmodium falciparum AMA1. PLoS One 6, e20977 (2011).
34. Milek, R. L., Stunnenberg, H. G. & Konings, R. N. Assembly and expression of a synthetic gene encoding the antigen Pfs48/45 
of the human malaria parasite Plasmodium falciparum in yeast. Vaccine 18, 1402–1411 (2000).
35. Mathias, D. K. et al. Expression, immunogenicity, histopathology, and potency of a mosquito-based malaria transmission-
blocking recombinant vaccine. Infect. Immun. 80, 1606–1614 (2012).
36. Healer, J. et al. Complement-mediated lysis of Plasmodium falciparum gametes by malaria-immune human sera is associated 
with antibodies to the gamete surface antigen Pfs230. Infect. Immun. 65, 3017–3023 (1997).
37. Read, D. et al. Transmission-blocking antibodies against multiple, non-variant target epitopes of the Plasmodium falciparum 
gamete surface antigen Pfs230 are all complement-fixing. Parasite Immunol 16, 511–519 (1994).
38. Niederwieser, I., Felger, I. & Beck, H. P. Limited polymorphism in Plasmodium falciparum sexual-stage antigens. Am J Trop Med 
Hyg 64, 9–11 (2001).
39. Escalante, A. A., Lal, A. A. & Ayala, F. J. Genetic polymorphism and natural selection in the malaria parasite Plasmodium 
falciparum. Genetics 149, 189–202 (1998).
40. Sheehy, S. H. et al. Phase Ia clinical evaluation of the safety and immunogenicity of the Plasmodium falciparum blood-stage 
antigen AMA1 in ChAd63 and MVA vaccine vectors. PLoS One 7, e31208 (2012).
www.nature.com/scientificreports/
1 4Scientific RepoRts | 5:11193 | DOi: 10.1038/srep11193
41. Douglas, A. D. et al. The blood-stage malaria antigen PfRH5 is susceptible to vaccine-inducible cross-strain neutralizing antibody. 
Nat Commun 2, 601 (2011).
42. Outchkourov, N. S. et al. Correctly folded Pfs48/45 protein of Plasmodium falciparum elicits malaria transmission-blocking 
immunity in mice. Proc Natl Acad Sci USA 105, 4301–4305 (2008).
43. Kocken, C. H. et al. Cloning and expression of the gene coding for the transmission blocking target antigen Pfs48/45 of 
Plasmodium falciparum. Mol Biochem Parasitol 61, 59–68 (1993).
44. Galli, G. et al. Adjuvanted H5N1 vaccine induces early CD4+ T cell response that predicts long-term persistence of protective 
antibody levels. Proc Natl Acad Sci USA 106, 3877–3882 (2009).
45. Douglas, A. D. et al. Tailoring subunit vaccine immunogenicity: maximizing antibody and T cell responses by using combinations 
of adenovirus, poxvirus and protein-adjuvant vaccines against Plasmodium falciparum MSP1. Vaccine 28, 7167–7178 (2010).
46. Elias, S. C. et al. Analysis of human B-cell responses following ChAd63-MVA MSP1 and AMA1 immunization and controlled 
malaria infection. Immunology 141, 628–644 (2014).
47. Haddad, D., Maciel, J. & Kumar, N. Infection with Plasmodium berghei boosts antibody responses primed by a DNA vaccine 
encoding gametocyte antigen Pbs48/45. Infect. Immun. 74, 2043–2051 (2006).
48. Milek, R. L. et al. Plasmodium falciparum: heterologous synthesis of the transmission-blocking vaccine candidate Pfs48/45 in 
recombinant vaccinia virus-infected cells. Exp Parasitol 90, 165–174 (1998).
49. Bushkin, G. G. et al. Suggestive evidence for Darwinian Selection against asparagine-linked glycans of Plasmodium falciparum 
and Toxoplasma gondii. Eukaryot Cell 9, 228–241 (2010).
50. Theisen, M. et al. A multi-stage malaria vaccine candidate targeting both transmission and asexual parasite life-cycle stages. 
Vaccine 32, 2623–2630 (2014).
51. Churcher, T. S. et al. Measuring the blockade of malaria transmission--an analysis of the Standard Membrane Feeding Assay. Int 
J Parasitol 42, 1037–1044 (2012).
52. Armistead, J. S. et al. Antibodies to a single, conserved epitope in Anopheles APN1 inhibit universal transmission of Plasmodium 
falciparum and Plasmodium vivax malaria. Infection and immunity 82, 818–829 (2014).
53. Duffy, P. E. & Kaslow, D. C. A novel malaria protein, Pfs28, and Pfs25 are genetically linked and synergistic as falciparum malaria 
transmission-blocking vaccines. Infect. Immun. 65, 1109–1113 (1997).
54. Gozar, M. M., Price, V. L. & Kaslow, D. C. Saccharomyces cerevisiae-secreted fusion proteins Pfs25 and Pfs28 elicit potent 
Plasmodium falciparum transmission-blocking antibodies in mice. Infect. Immun. 66, 59–64 (1998).
55. Cheru, L. et al. The IC(50) of anti-Pfs25 antibody in membrane-feeding assay varies among species. Vaccine 28, 4423–4429 
(2010).
56. Berthoud, T. K. et al. Potent CD8+ T-cell immunogenicity in humans of a novel heterosubtypic influenza A vaccine, MVA-
NP+ M1. Clin Infect Dis 52, 1–7 (2011).
57. Tameris, M. D. et al. Safety and efficacy of MVA85A, a new tuberculosis vaccine, in infants previously vaccinated with BCG: a 
randomised, placebo-controlled phase 2b trial. Lancet 381, 1021–1028 (2013).
58. Bustamante, P. J. et al. Differential ability of specific regions of Plasmodium falciparum sexual-stage antigen, Pfs230, to induce 
malaria transmission-blocking immunity. Parasite Immunol 22, 373–380 (2000).
59. Tachibana, M. et al. N-terminal prodomain of Pfs230 synthesized using a cell-free system is sufficient to induce complement-
dependent malaria transmission-blocking activity. Clinical and vaccine immunology : CVI 18, 1343–1350 (2011).
60. Miura, K. et al. Development and characterization of a standardized ELISA including a reference serum on each plate to detect 
antibodies induced by experimental malaria vaccines. Vaccine 26, 193–200 (2008).
61. Tsuboi, T. et al. Wheat germ cell-free system-based production of malaria proteins for discovery of novel vaccine candidates. 
Infection and immunity 76, 1702–1708 (2008).
62. Blagborough, A. M. & Sinden, R. E. Plasmodium berghei HAP2 induces strong malaria transmission-blocking immunity in vivo 
and in vitro. Vaccine 27, 5187–5194 (2009).
Acknowledgments
We thank J. Furze and the Jenner Institute Vector Core Facility for generating the recombinant viral 
vectors. We would also like to thank S. Moretz, A. Diouf, G. Tullo, and B. Deng for performing the 
SMFA; Dr Y. Wu for providing the recombinant Pfs25 protein and reference serum used in ELISAs; 
and Dr G. Christophides for providing the mosquitoes for midgut ELISA. As. MCK was a recipient 
of a Commonwealth Scholarship. SB is a NDM Leadership Fellow and a Junior Research Fellow of 
St. Catherine’s College at the University of Oxford. This work was funded by a Wellcome Trust grant 
(WT100157MA) to AVSH. SJD holds a MRC Career Development Fellowship (grant number G1000527) 
and is a Lister Institute Research Prize Fellow. S.C.G., S.J.D. and A.V.S.H. are Jenner Investigators. AC 
received funding from the European Community’s Seventh Framework Program (FP7/2007–2013) under 
grant agreements numbers 242095 and 223736 and DFD received an IRD fellowship. AMB is funded by 
Fraunhofer Institute and Medicines for Malaria Venture. SMFA work at NIH MFA Evaluation Centre 
was supported in part by the intramural program of the NIAID, NIH and in part by the PATH Malaria 
Vaccine Initiative. TT was supported in part by MEXT/JSPS KAKENHI grant numbers 23117008 and 
23406007. ALG was funded by a MRC clinical training fellowship grant number G0600424.
Author Contributions
M.C.K. performed the experiments, western blots, and statistical analysis on the immunogenicity data. 
D.F.D., I.S. and A.C. performed the feeding assays in Burkina Faso. K.M. and C.A.L. performed the 
feeding assays against P. falciparum NF54 at the NIH MFA Reference Facility. T.S.C. performed statistical 
analysis on all the feeding assays. M.C.K., A.M.B. and U.S. cultured P. falciparum NF54 and performed 
the immunofluorescence assays. S.J.D. and A.L.G. designed the Pfs25 construct. Y.L. and D.N. helped 
with the western blots. A.N. provided the ChAd63 viral vector. T.T. produced the recombinant proteins 
used in ELISAs. A.R.W., A.V.T., M.G.C., S.J.D. and S.C.G. provided advice on study design. M.C.K., 
R.E.S., A.V.S.H. and S.B. designed the study. M.C.K. and S.B. wrote the paper. All authors reviewed the 
manuscript.
www.nature.com/scientificreports/
1 5Scientific RepoRts | 5:11193 | DOi: 10.1038/srep11193
Additional Information
Supplementary information accompanies this paper at http://www.nature.com/srep
Competing financial interests: ARW, ALG, MGC, SJD, SCG and AVSH are named inventors on patent 
applications covering malaria vectored vaccines and immunization regimes. AN is an employee and/or 
shareholder in ReiThera Srl (former Okairos Srl) and is a named inventor on patents for ChAd63.
How to cite this article: Kapulu, M. C. et al. Comparative Assessment of Transmission-Blocking 
Vaccine Candidates against Plasmodium falciparum. Sci. Rep. 5, 11193; doi: 10.1038/srep11193 (2015).
This work is licensed under a Creative Commons Attribution 4.0 International License. 
The images or other third party material in this article are included in the article’s Creative 
Commons license, unless indicated otherwise in the credit line; if the material is not included under 
the Creative Commons license, users will need to obtain permission from the license holder to 
reproduce the material. To view a copy of this license, visit http://creativecommons.org/licenses/
by/4.0/
